Aripiprazole plus divalproex for recently manic or mixed patients with bipolar i disorder: A 6-month, randomized, placebo-controlled, doubleblind maintenance trial

Human Psychopharmacology

Volumn 26, Issue 8, 2011, Pages 543-553

  Woo, Young Sup ^a   Bahk, Won Myong ^a   Chung, Moon Yong ^b   Kim, Do Hoon ^c   Yoon, Bo Hyun ^d   Lee, Jong Hun ^e   Ahn, Yong Min ^f   Chung, Sang Keun ^g   Kim, Jeong Gee ^h   Lee, Kwang Heun ⁱ   Paik, Ki Chung ^j  

^a The Catholic University of Korea   (South Korea)

^b Seoul Veterans Hospital   (South Korea)

^c Hallym University Medical Center   (South Korea)

^d Naju National Hospital   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

^h Maryknoll Hospital   (South Korea)

ⁱ Dongguk University College of Medicine   (South Korea)

^j Dankook University   (South Korea)

more..

Author keywords

aripiprazole; bipolar disorder; divalproex; maintenance; relapse prevention

Indexed keywords

ARIPIPRAZOLE; FLURAZEPAM; LORAZEPAM; TRIAZOLAM; VALPROATE SEMISODIUM; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ALOPECIA; ANXIETY; ARTICLE; BIPOLAR I DISORDER; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADULT; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 83855161523     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1240     Document Type: Article

References (31)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorder, 4th edn (DSM-IV). American Psychiatric Press: Washington, DC.
2. Barnes TR,. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
3. Bowden CL, Janicak PG, et al., 1996. Relation of serum valproate concentration to response in mania. Am J Psychiatry 156: 765-770.
4. Bowden CL, Calabrese JR, Sachs G, et al., 2003. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60: 392-400.
5. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M,. 2010. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 71: 130-137.
6. Burris KD, Molski TF, Xu C, et al., 2002. Aripiprazole, a novel antipsychotic, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389.
7. Gitlin MJ, Swendsen J, Heller TL, Hammen C,. 1995. Relapse and impairment in bipolar disorder. Am J Psychiatry 152: 1635-1640.
8. Goldberg JF, Harrow M, Grossman LS,. 1995. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 152: 379-384.
9. Guy W,. 1976. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. US Department of Health, Education, and Welfare: Washington, DC; 534-537.
10. Inoue T, Domae M, Yamada K, Furukawa T,. 1996. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277: 137-143.
11. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA,. 2002. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441: 137-140.
12. Keck PE, Jr, Marcus R, Tourkodimitris S, et al., 2003. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160: 1651-1658.
13. Keck PE, Jr, Calabrese JR, McQuade RD, et al., 2006. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67: 626-637.
14. Keck PE, Jr, Calabrese JR, McIntyre RS, et al., 2007. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double blind study versus placebo. J Clin Psychiatry 68: 1480-1491.
15. Macritchie KAN, Geddes JR, Scott J, Haslam DRS, Goodwin GM,. 2001. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 3: CD003196.
16. Marcus R, Khan A, Rollin L, et al., 2011. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 13: 133-144.
17. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T,. 2002. Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 5 (suppl 1): S176.
18. McQuade RD, Stock E, Marcus R, et al., 2004. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 (suppl 18): 47-56.
19. Montgomery SA, Åsberg M,. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
20. Overall JE, Gorham DR,. 1962. The brief psychiatric rating scale. Psychol Rep 10: 799-812.
21. Simpson GM, Angus JW,. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl.): 11-19.
22. Solomon DA, Keitner GI, Miller IW, Shea MT, Keller MB,. 1995. Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry 56: 5-13.
23. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W,. 1997. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73: 159-171.
24. Strakowsky SM, Keck PE Jr, McEvoy SL, et al., 1998. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 55: 49-55.
25. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B, Trial 127 Investigators. 2009. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). Am J Psychiatry 166: 476-488.
26. Tohen M, Watemaux CM, Tsuang MT,. 1990. Outcome in mania: a 4-year prospective follow-up of 75 patients using survival analysis. Arch Gen Psychiatry 47: 1106-1111.
27. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL,. 2009. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord 116: 43-50.
28. Tolliver BK, McRAe AL, Verduin ML, Anderson SJ, Brady KT,. 2008. Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole-a case series. J Clin Psychopharmacol 4: 464-467.
29. Torrent C, Amann B, Sanchez-Moreno J, et al., 2008. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 118: 4-18.
30. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M,. 2008. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 109: 251-263.
31. Young RC, Biggs JT, Ziegler VE, Meyer DA,. 1978. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 133: 429-435.